AR signaling in Hormone Refractory Prostate Cancer
AR signaling in Hormone Refractory Prostate Cancer
批准号:
6683441
负责人:
Jacek Pinski
金额:
$8.1万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-01 至 2005-07-31
关键词:
androgen receptor androgens athymic mouse gene expression gene mutation hormone regulation /control mechanism hormone related neoplasm /cancer hormone sensitivity /resistance hormone therapy human tissue immunocytochemistry male neoplasm /cancer chemotherapy neoplasm /cancer therapy neoplastic process nucleic acid sequence patient oriented research prognosis prostate neoplasms prostate specific antigen prostate surgery protooncogene transcription factor
中文摘要
描述(由申请人提供):
英文摘要
DESCRIPTION (provided by applicant):
The androgen receptor (AR) mediates androgen signaling in the prostate and plays a vital role during all phases of prostate cancer development including the final androgen-independent phases. Somatic AR mutations, increased AR expression, increased AR coactivator expression and/or AR androgen-independent activity are all potential mechanisms causing prostate cancer progression to androgen-independent disease. Such aberrant AR activities might affect and/or predict time to hormone ablation therapy failure. Since clinical practice at present does not consider these mechanisms in choice or timing of treatment, we propose the use of aggressive chemotherapy and/or alternative androgen ablation treatments in conjunction with knowledge of the underlying mechanism of failure. We propose that response to chemo- or alternative hormone ablation therapy will be affected by the underlying AR mechanism of the original ablation therapy failure. In specific aim #1, we will measure AR mutations and expression levels of AR, p160 coactivators and HER2 in archival tissue from men in cohorts representing different stages of disease. In specific aim #2, we intend to do a preclinical trial using the CWR22 tumor model in mice to test early therapy and how it relates to the particular molecular abnormality biologically selected for during the course of androgen ablation treatment. Overall our work will provide a molecular framework of hormone resistant prostate cancer, important indices of prognosis, and the basis for several future clinical trials in alternative treatment strategies of androgen-independent prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
-
批准号:8318844
-
项目类别:
-
资助金额:$17.94万
-
财政年份:2010
-
负责人:Jacek Pinski
-
依托单位:
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
-
批准号:8135341
-
项目类别:
-
资助金额:$51.04万
-
财政年份:2010
-
负责人:Jacek Pinski
-
依托单位:
Targeted Therapy to Receptors for LH-RH in Prostate Cancer
-
批准号:8547781
-
项目类别:
-
资助金额:$30.35万
-
财政年份:2010
-
负责人:Jacek Pinski
-
依托单位:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
-
批准号:7982120
-
项目类别:
-
资助金额:$20.41万
-
财政年份:2008
-
负责人:Jacek Pinski
-
依托单位:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
-
批准号:7716722
-
项目类别:
-
资助金额:$1.44万
-
财政年份:2008
-
负责人:Jacek Pinski
-
依托单位:
PHI-54 A PHASE I STUDY OF IV FENRETINIDE IN PATIENTS WITH MALIGNANT SOLID TU
-
批准号:7603946
-
项目类别:
-
资助金额:$1.16万
-
财政年份:2006
-
负责人:Jacek Pinski
-
依托单位:
AR signaling in Hormone Refractory Prostate Cancer
-
批准号:6782582
-
项目类别:
-
资助金额:$8.13万
-
财政年份:2003
-
负责人:Jacek Pinski
-
依托单位:
海外基金